News

David S. Hong, MD, discusses larotrectinib and its mechanism of action.

The CAR T-cell therapy tisagenlecleucel showed promising anti-tumor activity in pediatric patients with acute lymphoblastic leukemia.

An abbreviated new drug application was approved by the FDA for leuprolide acetate injection as treatment of patients with advanced prostate cancer.

Adam Weiner, MD, discusses next steps for molecular testing in prostate cancer.

OTX-2002 has received an orphan drug designation by the FDA for patients with hepatocellular carcinoma. The agent will further be evaluated in the phase 1/2 MYCHELANGELO trial.

In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the results of the phase 3 CANOPY-A study.

Phase 2 trial of trilaciclib administered prior to sacituzumab govitecan-hziy in patients with unresectable, locally advanced, or metastatic triple-negative breast cancer demonstrates encouraging reductions in adverse events.

Based on findings from a phase 2 trial conducted by Memorial Sloan Kettering Cancer Center, the FDA has approved the use of cobimetinib for patients with histiocytic neoplasms.

A phase 1/2 clinical trial evaluating treatment with MRT-2359 in MYC-driven solid tumors has dosed its first patient and looks to improve early signals of clinical activity.

In an interview with Targeted Oncology, Marcin Dzienis, MD, further discussed the phase 4 trial of pembrolizumab plus carboplatin and paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.

A pooled analysis of 3 studies showed that there was an extended treatment benefit for patients with FRα positive recurrent ovarian cancer treated with the novel antibody-drug conjugate mirvetuximab soravtansine.

Following positive results and FDA action on pidnarulex in BRAC 1/2-positive ovarian cancer, a phase 1 study is exploring the agent in metastatic castration-resistant prostate cancer, in combination with talazoparib.

Leading local cancer center expands clinic reach to Laclede County with a new location.

Eytan M. Stein, MD, defines Menin inhibition and its role in the leukemia space.

A phase 1/2 study of ZN-c3, encorafenib, and cetuximab in patients with BRAF V600E-mutated colorectal cancer will begin, led by Zentalis Pharmaceuticals and Pfizer.

According to results from the SIERRA trial, Iomab-B may be an effective choice for patient with relapsed or refractory acute myeloid leukemia who are 55 years of age or older.

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.

Florida Cancer Specialists & Research Institute, LLC has submitted an application to participate in Medicare’s Enhancing Oncology Care Model, an alternative payment model that aims to address healthcare inequities, reduce costs, and improve and report outcomes for cancer patients.

Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.

Richard S. Finn, MD, discusses the background on lenvatinib and what led to the development of the LEAP-002 trial.

In the prespecified interim analysis of the COMMANDS trial for low-risk myelodysplastic syndromes, luspatercept had statistically significant and clinically meaningful improvements in red blood cell transfusion independence with no new safety signals.

Cristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.

In a unanimous vote, the FDA’s Oncologic Drugs Advisory Committee has voted that there is not enough evidence to conclude omburtamab improves overall survival in neuroblastoma with central nervous system/leptomeningeal metastases.

Physicians, clinicians and senior leaders of Florida Cancer Specialists & Research Institute, LLC will continue their long history of active involvement with the Florida Society of Clinical Oncology at the FLASCO Fall Session being held in Orlando, Oct. 28 & 29.

Positive efficacy and safety results from the phase 3 EPCORE™ NHL-1 trial have lead to an FDA application for approval of epcoritamab to treat relapsed or refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Alfred L. Garfall, MD, discussed the FDA approval of teclistamab, the MajesTEC-1 trial, and how this information should be used in the future.

Carolyn Owen, MD, discusses how the treatment landscape has shifted in chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Nicholas J. Short, MD, discussed the evolution of the treatment landscape for acute lymphoblastic leukemia and what he hopes is next to come.

Additional findings fro the phase 2 SOLO2 study shows that there is a need for research to determine the optimal strategy for patients who relapse after treatment with a PARP inhibitor.

The phase 3 CHART study reveals better survival with rezvilutamide plus androgen deprivation therapy vs bicalutamide and androgen deprivation therapy in metastatic, hormone-sensitive prostate cancer.